TVTX250117C2500
- 0.00
- 0.000.00%
Travere Therapeutic Newsroom
Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $33
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Analyst Ratings
H.C. Wainwright Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $22
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $45
Express News | Travere Therapeutics Inc : Guggenheim Raises Target Price to $45 From $41
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $24
Express News | Travere Therapeutics Inc: Expects Fiscal Year 2024 Net Product Sales to Be Approximately $227 Mln
Express News | Travere Therapeutics Inc: On Track to Provide Regulatory Update on Sparsentan in Fsgs by Its Q4 2024 Earnings Call
Press Release: Travere Therapeutics Provides Corporate Update and 2025 Outlook
Express News | Travere Therapeutics- Snda for Modification of Liver Monitoring for Filspari in Igan Accepted for FDA Review ; Pdufa Target Action Date of Aug 28
Express News | Travere Therapeutics Provides Corporate Update and 2025 Outlook
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability
Cantor Fitzgerald Initiates Travere Therapeutic(TVTX.US) With Buy Rating
Cantor Fitzgerald Initiates Travere Therapeutics at Overweight
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Announces Target Price $24
Travere Therapeutics Insider Sold Shares Worth $258,278, According to a Recent SEC Filing
J.P. Morgan's Top Healthcare Stocks for 2025
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $18